Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078296 | 1.00 | IDO1 (0.46) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL1115269 | 0.84 | MAPK8 (0.52) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL16257133 | 0.84 | IDO1 (0.46) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL892996 | 0.84 | MAPK8 (0.46) | MAPK8CES2CES1SIGMAR1RIPK1 | |
| SCHEMBL30148003 | 0.84 | MAPK8 (0.52) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL1288294 | 0.83 | IDO1 (0.48) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL1488965 | 0.82 | ERCC1 (0.47) | P2RX7 | |
| Hydrochloric Acid SCHEMBL8894497 | 0.82 | IDO1 (0.52) | IDO1AGXTMAPK8CES2CES1 | |
| SCHEMBL837008 | 0.82 | ALDH1A1 (0.46) | P2RX7KDM4E | |
| SCHEMBL503325 | 0.82 | TSHR (0.53) | IDO1AGXTMAPK8CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036014-B | Compound with AXL inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-09-07 | — | — | CN | disclosed |
| EP-3330272-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3330272-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-2931730-B1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-110036014-A | A kind of compound and its preparation and application with AXL inhibitory activity | 中国科学院上海药物研究所 | 2019-07-19 | — | — | CN | disclosed |
| CN-108250200-A | A kind of compound and its preparation and application with Axl inhibitory activity | 中国科学院上海药物研究所 | 2018-07-06 | — | — | CN | disclosed |
| WO-2018121228-A1 | COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2018-07-05 | — | — | WO | disclosed |
| EP-3330272-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3330272-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2997033-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006035282-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-5418239-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-23 | — | — | US | disclosed |
| US-5264454-A | Enzyme inhibitors, anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0481243-A1 | Tricyclic heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | DDO, DAO, SRR | IDO1 2500/4885AGXT 250/4885MAPK8 1937/4885 |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | PPARA, PPARG, PPARD | IDO1 4280/4885AGXT 918/4885MAPK8 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.